VaxTRIALS has been recognized
among the 10 best CROs
of 2022
In August 2022, the Life Sciences Review magazine recognized VaxTRIALS as part of the TOP 10 CROs of 2022, featuring theorganization at the forefront of the provision of CRO services, transformational for the industry.
Updated on June 14, 2023
News > VaxTRIALS has been recognized among the 10 best CROs of 2022
Our CEO, Jose Jimeno, emphasized that this achievement is thanks to the in-depth knowledge of our specialists' team on local regulations for managing vaccine clinical trials, coupled with an understanding of the needs of the industry; key pillars that have allowed us to manage more agile and flexible clinical trials, thus reducing time to market in vaccine clinical trials.
The publication highlights the importance of the comprehensive management achieved by VaxTRIALS, positioning the company as a leading player in the region. Its operation in more than 10 Latin American countries makes VaxTRIALS a strategic ally in terms of the trial's reliability and ethnic diversity as the region has become more prominent due to the easy access and varied population, aspects that provide safety and effectiveness in studies' results.
VaxTRIALS end-to-end involvement in studies, including clinical trial design, protocol, development, site identification, patient recruitment, clinical follow-up, reporting, and publication of data and studies, has been instrumental in licensing more than 6 vaccines to date.
VaxTRIALS will continue to transform and strengthen its vision in the immediate future in response to the worldwide challenges the industry faces, to remain the strategic partner of pharmaceutical companies, research centers, and health institutions whose common purpose is to contribute to eradicating preventable diseases in the world.
Read the full article "VaxTRIALS, Optimizing End-to-end Vaccine Trial Timeframes":
https://www.lifesciencesreview.com/vaxtrials
